Shares of Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Get Free Report) have earned a consensus rating of "Buy" from the four ratings firms that are currently covering the company, MarketBeat Ratings reports. Four research analysts have rated the stock with a buy recommendation. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $17.00.
ARTV has been the subject of several research analyst reports. HC Wainwright upgraded shares of Artiva Biotherapeutics to a "buy" rating and set a $12.00 target price for the company in a research report on Wednesday, June 11th. Needham & Company LLC dropped their target price on shares of Artiva Biotherapeutics from $23.00 to $18.00 and set a "buy" rating for the company in a research report on Thursday, May 15th.
Get Our Latest Stock Analysis on ARTV
Institutional Inflows and Outflows
Several hedge funds have recently made changes to their positions in the company. Bridgeway Capital Management LLC purchased a new position in shares of Artiva Biotherapeutics in the second quarter worth $53,000. Jane Street Group LLC purchased a new position in Artiva Biotherapeutics during the 2nd quarter valued at $67,000. Qube Research & Technologies Ltd purchased a new position in Artiva Biotherapeutics during the 2nd quarter valued at $58,000. Marshall Wace LLP bought a new stake in shares of Artiva Biotherapeutics during the 2nd quarter valued at $79,000. Finally, Y Intercept Hong Kong Ltd bought a new stake in shares of Artiva Biotherapeutics during the 2nd quarter valued at $48,000.
Artiva Biotherapeutics Price Performance
NASDAQ:ARTV traded down $0.07 on Tuesday, reaching $2.63. 9,736 shares of the company's stock were exchanged, compared to its average volume of 228,941. The stock has a fifty day simple moving average of $2.24 and a 200-day simple moving average of $2.91. Artiva Biotherapeutics has a 52 week low of $1.47 and a 52 week high of $17.31.
Artiva Biotherapeutics (NASDAQ:ARTV - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The company reported ($0.87) EPS for the quarter, missing analysts' consensus estimates of ($0.84) by ($0.03). Equities analysts forecast that Artiva Biotherapeutics will post -4.95 EPS for the current year.
Artiva Biotherapeutics Company Profile
(
Get Free Report)
Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.
Further Reading
Before you consider Artiva Biotherapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Artiva Biotherapeutics wasn't on the list.
While Artiva Biotherapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.